Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 1(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00639522Phase 1Unknown

Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma

Role: lead

NCT00881816Phase 1Unknown

Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Role: lead

NCT00881101Phase 1Unknown

Clinical Study of Liposomal Paclitaxel in Chinese Patients

Role: lead

NCT00606515Phase 4Completed

Pharmacokinetics Study of Liposomal Paclitaxel in Humans

Role: collaborator

All 4 trials loaded